OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with…
Read More
Press Releases
OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research…
OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting…
OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of…
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in…
OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation…
OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting…
OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR…
OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO)…
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced three poster presentations at…
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced that its lead clinical…
Clinically validated pH-sensitive nanomedicine platform allows for tumor specific delivery of protein therapeutics and increased…
ONM-501 shown to be promising immuno-therapeutic candidate for clinical evaluation in solid tumors SOUTHLAKE, Texas…
– Interim Phase 2 results presented at World Molecular Imaging Conference 2022 – – Pegsitacianine…
SOUTHLAKE, Texas – September 19, 2022 – OncoNano Medicine, Inc., a clinical-stage biotechnology company focused…
SOUTHLAKE, Texas – September 14, 2022 – OncoNano Medicine, Inc. today announced a presentation of…
– Oncology Development Veteran to Lead the Advancement of OncoNano’s Portfolio SOUTHLAKE, Texas – June…
SOUTHLAKE, Texas – May 10, 2022 – OncoNano Medicine, Inc. today announced the appointment of…
– ONM-501 is a dual-activating polyvalent STING agonist for immuno-oncology applications formulated with OMNI™, the…
SOUTHLAKE, Texas – April 12, 2022 – OncoNano Medicine, Inc. today announced positive results from…
March 10, 2022 SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced two poster presentations at the…
-Will convert previous grant awards to an equity investment in OncoNano’s Series B -Additional capital…
Update on pH-sensitive fluorescent nanoprobe from late-breaking oral presentation at The World Molecular Imaging Congress…
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology…
OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor…
OncoNano Medicine Announces Expanded Research Collaboration with UT Southwestern Medical Center to Advance Development of…
SOUTHLAKE, Texas – September 20, 2021 – OncoNano Medicine, Inc. today announced an oral presentation...
Read More
July 19, 2021 SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced a presentation at the 2nd Annual LifeSci…
Financing round led by Advantech healthcare investment team Funds will support Phase 3 program for…
SOUTHLAKE, Texas – August 27, 2019 – OncoNano Medicine, Inc. today announced that it has…
Southlake, TX. – June 26, 2020 – OncoNano Medicine, Inc. announced today the publication of…
– UTSW scientists demonstrate that a novel pH-sensitive polymer prolongs STING-mediated activation of innate immunity against…
- UTSW scientists demonstrate that a novel pH-sensitive polymer prolongs STINGmediated activation of innate immunity...
Read More
Mr. Driscoll’s deep experience in the biopharmaceutical industry particularly the immuneoncology field makes him ideally...
Read More
Findings indicate proof of mechanism and strong antitumor efficacy in preclinical models SOUTHLAKE, Texas –...
Read More
Findings indicate favorable tolerability and proof of mechanism in various solid tumors SOUTHLAKE, Texas –...
Read More
Grant to support expanded application of lead product, ONM-100, for imaging metastatic disease that may...
Read More
Publication data suggests ONM-100 was safe and provides preliminary feasibility data for use in resection...
Read More
Two abstracts and posters highlight the diverse applications of OncoNano’s ultra pH-sensitive micelle technology SOUTHLAKE,...
Read More
- Presentation will highlight the technology of pH-sensitive micelles for tumor-agnostic intraoperative detection of residual...
Read More
Funding will support pre-clinical and clinical development through Phase 1 trial of ONM500, an immunoadjuvant...
Read More
Proceeds will be used to support new and ongoing cancer imaging clinical trials and to...
Read More
ONM-100 was able to detect occult disease which was otherwise missed by standard surgery and...
Read More
FDA says proposed Phase 2 clinical trial may proceed SOUTHLAKE, TX. – January 4, 2019...
Read More
Results Selected for Poster presentation at San Antonio Breast Cancer Symposium SOUTHLAKE, TX. –December 5,...
Read More
The study, being conducted at TRACER Center of Expertise, University Medical Center in Groningen, The...
Read More
SOUTHLAKE, TX. – May 17, 2018 – OncoNano Medicine, Inc. today announced the closing of...
Read More